Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,504.47 86.94 0.60%
TOPIX 1,170.04 3.45 0.30%
HANG SENG 22,760.24 64.23 0.28%

Metamark Genetics Board of Directors Appoints Shawn M. Marcell President and Chief Executive Officer



 Metamark Genetics Board of Directors Appoints Shawn M. Marcell President and
                           Chief Executive Officer

Industry Veteran to Lead Metamark Genetics in Commercialization of Novel
Prognostic Tests for Prostate and Other Cancers

PR Newswire

CAMBRIDGE, Mass., April 30, 2013

CAMBRIDGE, Mass., April 30, 2013 /PRNewswire/ -- Metamark Genetics, Inc., a
leader in the discovery of novel molecular prognostic and diagnostic tests for
cancer, today announced that industry veteran Shawn M. Marcell has been named
the company's new president and chief executive officer. Mr. Marcell succeeds
interim executive Michael Kauffman, M.D., who will remain on Metamark's board
of directors. 

Metamark lead director Gregory C. Critchfield, M.D., said, "We are excited to
welcome Shawn to Metamark as the company prepares to launch its first
prognostic test, for prostate cancer. Shawn's broad and deep experience in
life sciences, and his success in bringing innovative products to market, make
him the ideal leader for Metamark as it grows into to a commercial
organization."  Dr. Critchfield added, "We also would like to thank Michael
Kauffman for his leadership during this important time in the company's
evolution."

"Metamark's strategy to develop novel prognostic and diagnostic tests based on
advanced quantitative histologic analysis has the potential to transform
approaches to cancer and other major diseases," said Mr. Marcell. "I am
thrilled to join the company and look forward to working with the entire team
as we build a leading commercial stage molecular diagnostics company."

Mr. Marcell has nearly three decades of diverse executive, commercial and
operational experience in life science and technology businesses. Most
recently, he was the lead executive, serving as general manager of Hologic's
(HOLX) wholly owned LIFECODES subsidiary, which was acquired by Immucor. He
headed commercial operations at Sequenom (SQNM), which acquired SensiGen,
where he served as president and CEO. Mr. Marcell has both CLIA laboratory and
product launch experience and has had additional key management roles with
Redpoint Bio, Prima Facie, Centocor and Abbott Diagnostics.

Mr. Marcell has been adjunct faculty and lecturer in Entrepreneurial Programs
at the Wharton School and has served on numerous for-profit and non-profit
boards.

About Metamark

Metamark Genetics is a privately held biotechnology company founded in 2007 to
develop new function- based prognostic and diagnostic tests aimed at improving
cancer care. The company's proprietary genomic and proteomic discovery
platforms have yielded significant discoveries in several disease areas,
including prostate, colon and breast cancers. During 2013, Metamark plans to
commercialize ProMark^TM – its lead prostate cancer prognostic test – through
its Cambridge, MA CLIA-certified laboratory.  For more information, please
visit the company's Website at www.metamarkgenetics.com.

Metamark^TM and ProMark^TM are trademarks of Metamark Genetics, Inc.

 

 

 

SOURCE Metamark Genetics, Inc.

Website: http://www.metamarkgenetics.com
Contact: Gary A. Cohen, Metamark Genetics, Inc., gcohen@metamarkgenetics.com,
617-583-1408
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement